MKI67 and breast carcinoma: The previous state-of-the-art knowledge in the field of predicting sensitivity to chemotherapy in breast cancer is limited to allocating chemotherapy to those patients with a high replicative fraction (i.e., high KI67 staining) or high-risk score in multigene expression panels.